Lupin gets USFDA nod for asthmatic symptoms prevention drug

Lupin gets USFDA nod for asthmatic symptoms prevention drug

Drug major Lupin on Tuesday said it has received approval from the US health regulator for its Albuterol Sulfate Inhalation Aerosol, used for treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms. The approved product is a generic version of ProAir HFA of Teva Branded Pharmaceutical Products R&D, Inc. In a regulatory filing, Lupin said it has received approval from the United States Food and Drug Administration (USFDA) for its Albuterol Sulfate Inhalation Aerosol, 90 mcg (base)/actuation.